Cat. No. | Product name | CAS No. |
DC7216 |
NVP-BSK805 dihydrochloride
Featured
NVP-BSK805 is a potent and selective ATP-competitive JAK2 inhibitor with IC50 of 0.5 nM; >20-fold selectivity towards JAK1, JAK3 and TYK2. |
1092499-93-8 |
DC7478 |
Pacritinib
Pacritinib (SB1518) is a potent and selective JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, respectively) and FLT3 (IC(50) = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50= 1280 and 520 nM, respectively). |
937272-79-2 |
DC8168 |
Peficitinib(ASP015K,JNJ-54781532)
Featured
Peficitinib(ASP015K,JNJ-54781532) is a novel potent JAK inhibitor, which demonstrated potent efficacy in adjuvant-induced arthritis model in rats. |
944118-01-8 |
DC11734 |
PF-06263276
PF-06263276 (PF06263276, PF 6263276) is a potent, selective pan JAK inhibitor with IC50 of 2.2, 23.1, 59.9 and 29.7 nM for JAK1, JAK2, JAK3, and TYK2, respectively. |
1421502-62-6 |
DC10779 |
PF-06651600
Featured
PF-06651600 is a potent JAK3-selective inhibitor with an IC50 of 33.1 nM. |
1792180-81-4 |
DC12489 |
PF-06700841 free base
Featured
PF-06700841 is an inhibitor of JAK1 and TYK2 kinases. PF-06700841 has been investigated for the treatment of psoriasis and lupus. |
1883299-62-4 |
DC12488 |
PF-06700841 tosylate
Featured
PF-06700841 is an inhibitor of JAK1 and TYK2 kinases. PF-06700841 has been investigated for the treatment of psoriasis and lupus. |
2140301-96-6 |
DC4230 |
Ruxolitinib (INCB018424)
Featured
Ruxolitinib is a potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively and is relatively less selective for JAK3 (IC50 = 322 nM). |
941678-49-5 |
DC8309 |
Ruxolitinib Phosphate
Featured
Ruxolitinib Phosphate is a potent and selective Janus kinase (JAK1, IC50 = 5.9 nM and JAK2, IC50 = 5.7 nM) inhibitor. |
1092939-17-7 |
DC10823 |
SAR-20347
Featured
SAR-20347 is an inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50s of 0.6, 23, 26 and 41 nM, respectively. |
1450881-55-6 |
DC8169 |
Solcitinib(GLPG0778)
Featured
Solcitinib, also known as GSK2586184 or GLPG0778, is a Janus kinase 1 (JAK1) inhibitor. |
1206163-45-2 |
DC7317 |
TG101209
Featured
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM, ~30-fold selective for JAK2 than JAK3, sensitive to JAK2V617F and MPLW515L/K mutations; TG101209 inhibit BRD4 activity with IC50 of 130 nM. |
936091-14-4 |
DC7318 |
TG101348(Fedratinib)
Featured
TG-101348 (SAR302503) is a selective inhibitor of JAK2 with IC50 of 3 nM, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3, TG-101348 also inhibit BRD4 with IC50 of 340 nM. |
936091-26-8 |
DC8511 |
TG-46
Featured
TG-46 is an inhibitor of JAK2, FLT3, RET, JAK3 with IC50 values of 6nM, 25nM, 17nM, 169nM respectively. |
936091-15-5 |
DC8510 |
TG-89
Featured
TG-89 is a JAK inhibitor. It has IC50 values of 6, 25, 17 and 169 nM against JAK2, FLT3, RET and JAK3 respectively. |
936091-56-4 |
DC8736 |
Tofacitinib
Featured
Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent versus JAK2 and JAK1. Phase 3. |
477600-75-2 |
DC5165 |
Tofacitinib (CP-690550) Citrate
Featured
Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent versus JAK2 and JAK1. Phase 3. |
540737-29-9 |
DC10431 |
Upadacitinib
Featured
Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders with an IC50 of 43 nM. |
1310726-60-3 |
DC7581 |
WHI-P154
Featured
WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation. |
211555-04-3 |
DC8080 |
WHI-P258
Featured
WHI-P258 is a negative control for JAK3 inhibitors. |
21561-09-1 |
DC9494 |
WHI-P97
Featured
WHI-P97 is a rationally designed potent inhibitor of JAK-3. |
211555-05-4 |
DC5022 |
XL019
Featured
XL019 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. |
945755-56-6 |